Insulet (PODD) Cash from Operations Growth (3y) (2013 - 2026)
Insulet (PODD) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -48.14% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 50.11% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -14.75% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 0.50% |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | 510.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 510.55% |
| Dec 31, 2025 | 53.48% |
| Sep 30, 2025 | 30.39% |
| Jun 30, 2025 | 98.04% |
| Mar 31, 2025 | 88.12% |
| Dec 31, 2024 | 98.19% |
| Sep 30, 2024 | 83.69% |
| Jun 30, 2024 | 68.02% |
| Mar 31, 2024 | 65.04% |
| Dec 31, 2023 | 38.54% |
| Sep 30, 2023 | 8.21% |
| Jun 30, 2023 | 18.56% |
| Mar 31, 2023 | 28.84% |
| Dec 31, 2022 | 2.63% |
| Sep 30, 2022 | 22.16% |
| Jun 30, 2022 | 22.10% |
| Mar 31, 2022 | -60.15% |
| Dec 31, 2021 | -41.58% |
| Sep 30, 2021 | -53.65% |
| Jun 30, 2021 | 70.84% |